News

Guy LaTorre to Join Antibiotic Adjuvant as Chief Executive Officer

Guy LaTorre to Join Antibiotic Adjuvant as Chief Executive Officer 150 150 adjuvant-admin

Gainesville, FL – The Company would like to announce the recent appointment of Mr. Guy LaTorre as Chief Executive Officer. Guy has over 25 years experience in the commercialization of medical devices in the regenerative medicine, oral care and IVD space. Prior to this, Guy has held numerous executive management positions including CEO of Breathtec Biomedical Inc., COO for Armor Dental Corp. and co-founder and Vice President of Business Development at Novamin Technology Inc.
Guy LaTorre
“I am very excited about the direction of the Company, the quality of the team and the important work we are doing to address the overuse and misuse of antibiotics”. LaTorre says about joining the Antibiotic Adjuvant team.

David Flores, the acting CEO, will be the Chief Operating Officer. “We are extremely excited to bring someone with the experience that Guy has to our leadership team. It shows the potential that our product has and how we are evolving as a company.” Flores says about the news.

About Antibiotic Adjuvant: Antibiotic Adjuvant is a digital health startup addressing the problem of antibiotic misuse to reduce antibiotic resistance, improve patient outcomes, and reduce the patient cost of care. Our first product, SmartSteward, optimizes antibiotic use on skilled nursing facilities. We have 3 active pilots and are developing our platform with our experienced team and selected nursing home staff including physicians, nurses and pharmacists.

Antibiotic Adjuvant Selected as Part of the Sweet 16 for the Cade Prize

Antibiotic Adjuvant Selected as Part of the Sweet 16 for the Cade Prize 1280 914 adjuvant-admin

Gainesville, FL – Antibiotic Adjuvant has been selected as a finalist for the Cade Prize to be held September 29, 2018. The Cade Prize serves to identify, recognize, and celebrate inventive minds and innovation in the state of Florida. Since its launch in 2010, the Cade Prize competition has drawn applications from hundreds of creative thinkers and cutting-edge ventures in IT, healthcare, biomedicine, environmental science, and agriculture, to name a few.

“We are very excited to be among such a distinguished group of startups,” remarks David Flores, CEO of Antibiotic Adjuvant. “After completing IndieBio in April, we have been actively looking for pitching competitions in Florida to build relationships with investors,” mentions Flores about their fundraising efforts and how they see this competition helping their digital health startup.

Out of the 100+ submissions, 16 have been selected to be the Sweet 16. For 2018, cash prizes will be awarded to the top four rankings. The Final Four will be named at the 4th annual Inventivity Bash. First place will be awarded $25,000, second place $15,000, third place $7,500, and fourth place $2,500.

About Antibiotic Adjuvant: Antibiotic Adjuvant is a digital health startup addressing the problem of antibiotic misuse to reduce antibiotic resistance, improve patient outcomes, and reduce the patient cost of care. Our first product, SmartSteward, optimizes antibiotic use on skilled nursing facilities. We have 3 active pilots and are finishing our minimum viable product.

About the Cade Museum: In 2004, Dr. James Robert Cade and his family established the Cade Museum Foundation to design and build a museum in Gainesville, Florida. The mission of the museum is to transform communities by inspiring and equipping future inventors, entrepreneurs, and visionaries. Dr. Cade, a physician at the University of Florida, was best known as the leader of the research team that invented Gatorade in 1965.

Antibiotic Adjuvant to Present at IndieBio Demo Day

Antibiotic Adjuvant to Present at IndieBio Demo Day 150 150 adjuvant-admin

News Release

Antibiotic Adjuvant’s founders David Flores, Luis F Garcia, and Robert Yancey, MD to take the stage at the biotech accelerator’s Demo Day on April 17 in San Francisco.

SAN FRANCISCO, CA, APRIL 11, 2018—Antibiotic Adjuvant will present its software to reduce antibiotic resistance and antibiotic overuse from the stage at IndieBio Demo Day on April 17, 2018. Antibiotic Adjuvant will join thirteen other companies that have completed the accelerator’s fourmonth biotech training program. A full list of the Class 6 companies can be found on the IndieBio website at indiebio.co/introducing-indiebio-class-six/.

Antibiotic Adjuvant uses existing medical history from a patient, and the facility’s ecology information to provide personalized recommendations to the doctor before they make an antibiotic prescription. The data is analyzed to create an antibiotic stewardship program that uses real-time information to make decisions and can adapt to changes in the facility’s microbiome. Then, using machine learning, it can predict resistant infection, complications, and resistance patterns.

“We are extremely proud to speak at Demo Day and share how we can improve patient outcomes and save hospitals and nursing facilities millions of dollars by implementing antibiotic stewardship programs the right way,” said Flores. “We are optimizing the use of antibiotics, lowering antibiotic resistance, and the number of hospital-acquired infections. Having proved the concepts manually, we have now created a scalable software to affect every antibiotic prescription in a health center.”

Since its first class launched in 2015, IndieBio has provided seed funding, mentorship and R&D tools for 81 companies, whose work tackles global challenges including food security, access to life-saving medical treatments and sustainable materials. As the first seed stage biotechnology accelerator, IndieBio is designed to turn scientists into entrepreneurs, providing them with the business and technical skills to build transformative businesses. Previous IndieBio alumni include Memphis Meats, Koniku, SyntheX, Catalog, Ava Winery, and Qidni Labs.

“This class is an incredible example of what can happen when you give scientists the tools to bridge the gap between research and entrepreneurship,” said IndieBio founder Arvind Gupta. “The life sciences are going through a massive period of disruption, changing in new and exciting ways as people begin to think about biology as a true technological field. The fourteen companies presenting at Demo Day next week are tackling some of the most daunting challenges we face today, and we’re excited to see the impact they will have moving forward.”

Media Contact:

David Flores, 305-322-9378, david@a-adjuvant.com

About Company Antibiotic Adjuvant

Antibiotic Adjuvant leverages health data and machine learning to control antibiotic resistance and healthcare associated infections. Their software help facilities improve patient outcomes and saves millions of dollars in compliance cost for Antibiotic Stewardship and Infection Control Program requirements by optimizing antibiotic usage.

http://antibioticadjuvant.com/

About IndieBio

IndieBio (@IndBio) is the world’s leading accelerator for biotech startups. The IndieBio accelerator program uniquely provides founders with a fully equipped lab, world class mentors and significant seed funding to foster the next generation of biotech entrepreneurs. Notable alumni include Memphis Meats, Koniku, SyntheX, Catalog, Ava Winery, and Qidni Labs.